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Microtubules are dynamic and structural cellular components involved in several cell functions, including cell shape, motility, and
intracellular trafficking. In proliferating cells, they are essential components in the division process through the formation of the
mitotic spindle. As a result of these functions, tubulin and microtubules are targets for anticancer agents. Microtubule-targeting
agents can be divided into two groups: microtubule-stabilizing, and microtubule-destabilizing agents. The former bind to the
tubulin polymer and stabilize microtubules, while the latter bind to the tubulin dimers and destabilize microtubules. Alteration of
tubulin-microtubule equilibrium determines the disruption of the mitotic spindle, halting the cell cycle at the metaphase-anaphase
transition and, eventually, resulting in cell death. Clinical application of earlier microtubule inhibitors, however, unfortunately
showed several limits, such as neurological and bone marrow toxicity and the emergence of drug-resistant tumor cells. Here
we review several natural and synthetic microtubule-targeting agents, which showed antitumor activity and increased efficacy in
comparison to traditional drugs in various preclinical and clinical studies. Cryptophycins, combretastatins, ombrabulin, soblidotin,
D-24851, epothilones and discodermolide were used in clinical trials. Some of them showed antiangiogenic and antivascular activity
and others showed the ability to overcome multidrug resistance, supporting their possible use in chemotherapy.
1. Introduction
Microtubules are dynamic and structural cellular compo-
nents, typically formed by 13 protofilaments, which constitute
the wall of a tube; each of the protofilaments consists of
a head-to-tail arrangement of 𝛼/𝛽 tubulin heterodimers
[1]. They are involved in several cell functions, includ-
ing cell shape, motility, and intracellular trafficking. In
proliferating cells, they are one of the essential compo-
nents in the division process through the formation of the
mitotic spindle. This event can take place because of the
dynamic nature of microtubules through polymerization
and depolymerization cycles [2]. As a result of these func-
tions, tubulin and microtubules are targets for anticancer
agents [3, 4]. Microtubule-targeting agents can be divided
into two groups: microtubule-stabilizing and microtubule-
destabilizing agents. The former bind to the tubulin polymer
and stabilizemicrotubules, while the latter bind to the tubulin
dimers and destabilize microtubules [5, 6].
Despite these differences, alteration of tubulin-
microtubule equilibrium leads to the same final result:
it disrupts the mitotic spindle, halting the cell cycle at the
metaphase-anaphase transition and eventually resulting in
cell death [7] (Figure 1).
Clinical application, however, has unfortunately shown
several limits, such as a high level of neurological and bone
marrow toxicity and the emergence of drug-resistant tumor
cells due to the overproduction of P-glycoprotein (Pgp),
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Figure 1: The dynamic nature of cytoskeleton is due to cycles
of microtubule catastrophes. (a) Model structure of assembled
cytoskeleton. The variety of shapes and sizes of the microtubule
cytoskeleton is as great as the number of different cell types. In
interphase, microtubules are long and stable because there are
almost no catastrophes. (b) In mitosis, catastrophes are relatively
frequent, resulting in highly dynamic microtubules that reach a
steady-state length after a few minutes of growth (c). (d) After
the segregation of chromatids, a new cycle of depolymerization
and polymerization begins, resulting in a new stable microtubule
cytoskeleton in daughter’s cells (d). Blue and red arrows indicate
effects of stabilizing and destabilizing agents, all resulting in cell
cycle arrest.
an ATP-binding cassette (ABC) transmembrane transporter
[8], the overexpression of different beta-tubulin isotypes,
including 𝛽III-tubulin [9, 10], or tubulin mutations [11].
Several natural and synthetic microtubule-targeting
agents, exhibiting antitumor activity and increased efficacy
in comparison to traditional drugs in various preclinical and
clinical studies, have been discovered and their mechanisms
have been elucidated [12, 13]. Apart from the well-known
antimitotic function, for some of these drugs antiangiogenic
and antivascular activity were demonstrated; for others the
ability to overcome multidrug resistance was found. Many of
these new generation microtubule-targeting agents are still
under evaluation for clinical use. Some of them showed good
tolerability and antitumor activity in particular cancers.
This review provides an overview of those microtubule-
targeting drugs which are to date under clinical evaluation.
A particular attention will be paid to the translation of
preclinical data into the design of clinical trials.
2. Microtubule-Destabilizing Agents
Colchicine and Vinca alkaloids are two of the first
microtubule-destabilizing agents to be discovered.These two
compounds depolymerize microtubules by interacting with
various 𝛽-tubulin sites. In particular, Vinca alkaloids interact
with tubulin at specific binding sites which differ from those
of other agents, including colchicine or taxanes, interfering
with microtubule dynamics, blocking polymerization at
the end of the mitotic spindle, and leading to metaphase
arrest. Thanks to their peculiar mechanism of action, Vinca
alkaloids have beenwidely used in anticancer therapy, usually
in combination with other chemotherapeutic agents which
do not have cross-resistance with them. First-generation
Vinca alkaloids such as vinblastine have been included in
the treatment protocol of both Hodgkin and non-Hodgkin
lymphomas and testicular carcinoma, while vincristine
has been approved for several years in the treatment of
hematological tumors such as acute leukemia and multiple
myeloma but also of rare tumors such as rhabdomyosarcoma
and neuroblastoma. However, vincristine treatment was
associated with a severe neurotoxicity, while the suppression
of the bone marrow was more frequently reported during
vinblastine therapy [14]. Second-generation semisynthetic
Vinca alkaloids, vinorelbine and vindesine, have shown a
broader spectrum of antitumor activity in vitro, along with a
decreased neurotoxicity. Vinorelbine was approved as single
agent and in combination therapy for the treatment of both
hematological and solid tumors, including lung cancer, breast
cancer, and gynecological tumors [15]. Recently, another
synthetic Vinca alkaloid, vinflunine, has been approved in
Europe for the second-line treatment of metastatic urothelial
carcinoma. It is the first fluorinated microtubule inhibitor,
which was associated with a higher antitumor activity than
other Vinca alkaloids, showing also an excellent safety profile
[16].
In order to overcome the clinical limits of these agents,
in the last years attention has been focused on natural and
synthetic compounds with a different structure but which act
in a similar way [7, 17] (Table 1).
2.1. Cryptophycins. Cryptophycins are synthetic derivatives
of macrocyclic depsipeptides, isolated by Nostoc sp. [18].
They block cell division and prevent the correct formation
of the mitotic spindle, by inhibiting tubulin polymerization,
probably at the binding site of the Vinca alkaloids [19]. In
particular, C-52 and C-55 induce apoptosis by means of Bcl-
2 hyperphosphorylation and inactivation [20–22] (Figure 2).
These compounds are able to induce this phosphorylation at a
greater extent than othermicrotubule inhibitors [23].Thefirst
form discovered was epoxide cryptophycin 1, which showed
antitumoral activity both in preclinical in vitro (colon, breast,
ovarian, lung, and nasopharyngeal carcinomas) and in vivo
(lung, breast, and prostate tumors) models. This has led to
isolation and synthesis of cryptophycin analogs, divided into
epoxides, chlorohydrins, and glycinate chlorohydrins [24]
(Figure 3).
Cryptophycin 8 is the first C-1 analog synthesized in order
to improve its antitumoral efficacy by means of conversion
of the epoxide group into chlorohydrin. Its activity has been
shown both in murine and human tumors. Although it is
not as powerful as C-1, it is more soluble in water and has a
stronger therapeutic effect.Nevertheless, it is still too unstable
in solution to be considered clinically relevant [25].
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Table 1: Microtubule-destabilizing agents.
Chemical lead Properties and effects Clinical trial/status References
Cryptophycins Apoptosis induction. Synergistic withchemotherapy and radiation.
Phase II clinical trials in
platinum-resistant ovarian cancer and in
NSCLC (C-52) but withdrawn due to
peripheral neuropathy.
[26, 28, 31, 32, 36]
Combretastatin A-4-P
Antivascular and antiangiogenic activity.
Synergistic with radiation, hyperthermia,
chemotherapy, and immunoradiotherapy.
Phases II and III clinical trials in
advanced solid tumors (lung and thyroid
cancer) and in combination with
carboplatin.
[63, 64, 66–70, 72, 73]
Combretastatin A-1-P
Antivascular and antitumoral activity
superior to CA-4-P. Synergistic with
chemotherapy.
Phase I clinical trials in solid tumors and
in acute myelogenous leukaemia and
myelodysplastic syndromes.
[78, 79]
Ombrabulin
Antivascular and antitumoral activity
superior to CA-4-P. Synergistic with
chemotherapy.
Phase I clinical trials as a single agent or
in combination; phase III clinical trial in
advanced soft-tissue sarcoma.
[86]
Soblidotin
Apoptosis induction. Antivascular
activity. Antitumoral activity in tumors
resistant to vincristine, docetaxel, and
paclitaxel.
Phase II clinical trials in advanced solid
tumors (soft-tissue sarcoma, NSCLC). [99–105]
D-24851
Curative at nontoxic doses in rat tumor.
No neurotoxic effects. Oral applicability.
Activity versus MDR cell lines.
Phase I/II clinical trials in advanced solid
tumors. [140, 141]
Pseudolaric acid B
Antiangiogenic activity. No neurotoxic
effects in tested animal. Activity versus
MDR cell lines.
Preclinical phase. [148, 149]
Embellistatin Antiangiogenic activity. Preclinical phase. [150]
Induce Bcl-2 phosphorylation
Cryptophycins
Inhibit polymerization
Bcl-2
inhibition
Apoptosis
in G2/M
Mitotic arrest
and destabilize microtubules
Figure 2: Mechanism of action of cryptophycins.
Cryptophycins
Epoxides
Chlorohydrins
Glycinate
chlorohydrins
C-1, C-52, C-292
C-8, C-55, C-296, C-283
C-249, C-55gly, C-309, C-283gly
Figure 3: Classification of cryptophycins.
2.1.1. Cryptophycins 52 and 55. Cryptophycin 52 (LY355703)
is a synthetic epoxide, used in phase II clinical trials, which
presents a cytotoxic effect 400 times stronger than paclitaxel
and Vinca alkaloids [26, 27]. It shows in vitro antitubulin,
antimitotic, and cytotoxic activity which is dose-dependent
against tumor cells. Furthermore, its activity has been eval-
uated both in murine tumor models and in human tumor
xenografts [23]. C-52 resulted to be also effective against
multidrug-resistant tumors [26, 28, 29].
Paclitaxel and the Vinca alkaloids are sensitive to the
multidrug resistance (MDR) transporters P-glycoprotein (P-
gp, MDR-1) and/or MDR-associated protein (MRP-1). Cryp-
tophycin 52 was tested for its sensitivity to multidrug resis-
tance in several paired cell lines in which a sensitive parental
line was matched with a multidrug-resistant derivative line.
Compared to other antimitotic agents (paclitaxel, vinblas-
tine, and vincristine), the potency of cryptophycin 52 was
shown to be minimally affected in multidrug-resistant cells
compared to their sensitive parental lines [30]. Cryptophycin
52 fragment A analogues was synthesized to improve the
potency and the aqueous solubility of the molecule allowing
for the modification of its formulation. However, the same
functional groups that rendered these analogues more potent
and more water soluble also contributed to making them
better substrates of the Pgp efflux pump. It is an unacceptable
feature in the development of a clinically relevant antitumor
agent [29].
Preclinical toxicological studies on animals (rats and
dogs) have shown that above a certain concentration level C-
52 causes secondary effects such as neutropenia and gastroin-
testinal problems but not neurotoxicity. These studies have
allowed evaluating the optimum phase II dosage and tracing
the plasma pharmacokinetic profile [26]. Furthermore, phase
I clinical trials identified 1.5mg/m2 as a well-tolerated dose
level of C-52. It was delivered as a 2-hour i.v. infusion on
day 1 and day 8 repeated every 3 weeks [31]. This schedule
was employed in a phase II study to determine the activity
of C-52 in non-small cell lung cancer (NSCLC) patients
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previously treated with platinum-based chemotherapy and
to characterize its toxicity profile. A good rate of disease
stabilization and an unacceptable toxicity was found in this
setting [32]. Also, a multicenter trial was performed to
evaluate the same schedule of the drug in patients with
platinum-resistant advanced ovarian cancer. A considerable
clinical benefit without serious adverse events was achieved
[28]. Afterwards, these phase II clinical trials were terminated
due to significant neurological toxicity [12].
Cryptophycin 55, a C-52 chlorohydrin, shows higher
cytotoxic activity and therapeutic efficacy than its epoxide
precursor, but its low stability in solution has delayed its
clinical application [33]. This problem has been overcome,
however, by means of the synthesis of glycinate esters (C-
55gly, C-283gly, and C-309) which show not only an in vivo
activity similar to their precursors but also a high level of
stability [34].
Treatment with C-52 and C-55 combined with other
chemotherapy agents has produced synergic effects without
increased toxicity, bringing about a greater survival rate
in ovarian carcinoma murine models [23, 28]. The use of
human tumor xenografts has made it possible to evaluate C-
52 and C-55 activity combined with cisplatin, carboplatin,
and oxaliplatin in different tumors. C-52 showed a synergic
effect only when associated with cisplatin, whereas C-55
showed increased activity with all the platinum compounds
[35]. In vivo antitumoral activity of C-52 and C-55 has
been assessed in combination with radiotherapy (2𝛾) or
with 5-FU in tumor xenografts, showing an increased effect.
Pharmacokinetic analyses performed in murine models have
demonstrated that C-52 concentration in the tumor increased
after administration and remained high for 24 hours. The
mean life of C-55 was the longest in the liver, intermediate in
tumor tissue, and less in plasma. After C-55 administration,
the mean life of C-52 was the longest in tumor tissue, less
in plasma, and even less in the liver, suggesting almost total
conversion of C-55 into C-52 in the tumor. The greater C-52
accumulation in tumor tissue depends on the bioconversion
of C-55 in C-52 and different binding affinities towards
different tissue proteins. The use of C-55 to deliver C-52
increased the retention of C-52 in tumor tissue and reduced
its presence in all studied normal tissues. Furthermore,
extracellular acid pH of the tumor increased C-55 stability,
whereas intracellular basic pH encouraged bioconversion by
stimulating its pharmacological activity [36].
The obtained results indicated that C-52 and C-55 ful-
filled all the criteria required by ideal chemotherapy agents,
since they showed an action mechanism against a specific
target and considerable activity against drug-resistant cells.
However, the lack of response observed in some tumors
and peripheral neuropathy have been limiting factors in the
development of these agents leading to termination of their
study.
2.1.2. Second-Generation Cryptophycins. C-309, C-249, and
C-283 are second-generation candidates for clinical use. The
first two are glycinate esters, synthesized in order to provide
a higher chemical stability and more solubility in water. C-
309 is a derivative of C-296 which has proved to have more
therapeutic activity than C-55, C-283, C-249, and C-296; it is
able to bring about a complete or partial regression of murine
tumors at lower doses than those of other glycinate analogs.
C-249 derives from C-8 and is active against MDR tumors.
Moreover, it has the advantage of being easier to synthesize.
These second-generation analogs have proved to be up to
1000 times as active as those of the first clinical candidates
(C-52) but with the same or even less toxicity [34].
2.2. Combretastatins. The combretastatins, isolated from
Combretum caffrum, are molecules structurally related to
colchicine which have been extensively developed since the
late 1990s as vascular-disrupting agents (VDAs) [37]. The
vascular-disrupting effect of these compounds is present well
below the maximum tolerated dose, with a wide therapeutic
window [38]. A number of combretastatins are currently
in clinical trials: combretastatins A4- and A1-phosphate,
verubulin, crolibulin, plinabulin, and ombrabulin [12].
2.2.1. CA-4-P. Combretastatin A-4 interacts with tubulin
at the colchicine binding site but not in the same pseu-
doirreversible manner. It is used as a combretastatin A-
4 3-O-phosphate (CA-4-P), a prodrug which is soluble in
water and transformed into its active form by endogenous
phosphatases [39]. It showed cytotoxicity in tumor cell lines
and in human endothelial cells, HUVEC, which are sensitive
to the drug only if they are actively proliferating, suggesting
a potential use as an antiangiogenic agent [38]. By interfering
with microtubule polymerization and with mitotic spindle
assembly, CA-4-P induces G2/M arrest, thus bringing about
cell death by either mitotic catastrophe or apoptosis [38, 40,
41].
Recent computational studies, using fluorescence spec-
troscopy, identified a potential binding site on 𝛾-tubulin
for both CA-4-P and colchicines [42]. Since high levels of
𝛾-tubulin have been reported in poorly differentiated and
aggressive brain tumors, such as human glioblastoma and
medulloblastoma [43, 44] and lung [45] and breast cancer
[46], the discovery of a potential site interaction on this
molecule would offer the possibility of targeting inhibition
with a new class of chemotherapeutic agents. However, the
experimental validation of such interesting observation is
underway.
CA-4-P (also known as Zybrestat or fosbretabulin) shows
a potent in vivo antivascular activity since it causes a rapid
and widespread reduction of the tumoral blood flow and
an increased vascular resistance, effects which are extremely
reduced in the normal tissues [47]. At a dose of 1/5–1/10
of the maximum tolerated dose (MTD), the central area
of the tumor undergoes hemorrhagic necrosis, while a thin
peripheral ring of live cells remains [38, 48, 49]. On the con-
trary, colchicine and other drugs act only at approximately
MTD [50]. This constitutes an important advantage for the
therapeutic application of CA-4-P. An immediate effect of
CA-4-P treatment is an increased vascular permeability,
which is important for the reduction of blood flow through
vascular collapse, and an increased viscosity consequent to
fluid loss from the vasculature. However, endothelial barrier
function alterations and increased vascular permeability
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might contribute to hastening tumor cell extravasation,
causing progression to stages of greater malignancy, with
heightened invasiveness and, in some cases, increased distant
metastasis. It is no coincidence that susceptibility of tumors
to CA-4-P showed a positive correlation with tumor vascular
permeability [51]. Experiments conducted on HUVEC cells
have shown that the CA-4-P-inducted microtubule depoly-
merization triggers off the actin reorganization through Rho
activation and MLC (Myosin Light Chain) phosphorylation,
thus causing rounding and retraction of cells and mem-
brane blebbing. These events are associated with increased
permeability, while the morphological cell change might
contribute to determining the effects observed in vivo by
means of vascular constriction [52, 53]. Furthermore, since
CA-4-P interferes with the formation of stress fibers, it
inhibits the VE-cadherin/𝛽-catenin complex, thus leading
to the destabilization of cell-cell junctions and increasing
endothelial permeability [54].
The ex vivo perfusion of animal tumors highlights a
lower increase in vascular resistance to that found in vivo,
suggesting that the blood might also contribute towards the
antivascular action of the drug [48]. It has been demonstrated
that CA-4-P induces increased expression of endothelial
CAM, responsible for the observed neutrophil recruitment
which in vivo probably contributes both to vascular damage
and to tumor cell death [55].
Apart from being an antivascular agent, CA-4-P inhibits
the formation of new blood vessels, both in vitro and in
vivo, presumably through inactivation of the VE-cadherin/𝛽-
catenin complex and Akt, all proteins required for cell
adhesion, survival, and proliferation during neoangiogenesis.
The same study has shown that smooth muscle cells, which
are resistant to the drug, interfere with its antiangiogenic
activity in vitro, suggesting that they may confer resistance
to the endothelium by stabilizing cell-cell junctions [54]. CA-
4-P selectivity towards the neoplastic tissue might therefore
depend on the immaturity of tumor vessels, together with
the proliferative status of tumor endothelial cells. Moreover,
CA-4-P reduces in vitroHIF-1 expression (Hypoxia Inducible
Factor-1) under hypoxiamainly in endothelial cells compared
to that in cancer cell lines, suggesting a further possible
mechanism of action for the drug [56] (Figure 4).
However, the effects of CA-4-P on tumor growth are
not particularly significant, probably because of the per-
sistent presence of vital peripheral cells [50], although the
administration of several doses compared to the same total
dose of the drug does increase its antitumoral effect [57,
58]. Furthermore, CA-4-P activity is directly proportional
to tumor size [49]. This aspect, together with its capacity to
act on the tumor core, differentiates this drug from more
common therapeutic approaches, which target the peripheral
tumor area. These complementary properties, together with
the limited action of CA-4-P as a single agent, have led
to experimentation involving combined treatments. It has
been demonstrated that CA-4-P increases the response to
radiotherapy and hyperthermia in treated tumors [57, 59]
and, what is more, leads to a 90% increase in the retention
of the anti-CEA antibody marked with I131 in the tumor,
which is eradicated in 83%of the cases [60]. Similarly, CA-4-P
increases the effect of chemotherapy drugs such as cisplatin,
vinblastine, 5-fluorouracil, and irinotecan [57, 61].
The overall in vivo results obtained with CA-4-P have
led to its introduction in phase I clinical trials [12, 62–
66]. A phase I trial was performed to determine the MTD,
safety, and pharmacokinetic profile of CA-4-P. This study
showed absence of traditional cytotoxic side effects, with a
toxicity profile which seems consistent with a “vascularly
active” drug [67, 68]. The effects on tumor blood flow
were assessed using dynamic contrast-enhanced magnetic
resonance imaging (DCE-MRI) techniques. Dosages < or =
60mg/m2, as a 10min infusion at 3-week intervals, define
the upper boundary of the MTD. Similar effects were seen in
other phase I clinical trials using a weekly and daily schedule
[69, 70]. Afterwards, a further phase I trial investigated
the combination of CA-4-P with carboplatin. A greater
thrombocytopenia was observed as a consequence of altered
carboplatin pharmacokinetics [63].
In order to improve its efficiency and reduce its side
effects, a specific therapeutic system has been realized,
based on the use of liposomes containing CA-4-P, carrying
superficial RGD-peptides able to bindwith the𝛼v𝛽3 integrins
overexpressed on proliferating tumor endothelium. In vitro
tests have demonstrated the specificity and stability of the
system, essential properties for its in vivo application [71]. To
date, phase II/III clinical trials in lung and thyroid cancer
are currently being evaluated [12]. These studies showed
that CA-4-P with or without carboplatin and paclitaxel
combination therapy was well tolerated in thyroid cancer
patients, although it did not meet statistical significance in
OS improvement [72]. Instead, preliminary data suggests
survival benefits and increased responses without significant
additional toxicity in NSCLC patients treated with CA-4-P in
combination with carboplatin, paclitaxel, and bevacizumab
compared to patients treated with carboplatin, paclitaxel, and
bevacizumab only [73].
2.2.2. CA-1-P. Combretastatin A1 phosphate (also known as
Oxi4503), a CA-1 water-soluble prodrug, shows a powerful
antivascular activity.Whenused inmurine and human tumor
xenografts at much lower doses than those required by CA-4-
P, CA-1-P brings about a drastic reduction of blood flow, with
resulting necrosis [74]. CA-1-P causes an increase in vessel
permeability, in VEGF production and apoptosis induction
in endothelial cells [75]. At high doses it is more easily
tolerated than CA-4-P and shows a much higher antitumoral
activity, leading to complete regression of human tumors
even at extremely low doses [74]. Excellent results have
been obtained with combined treatments involving several
chemotherapy agents [76].
In vitro pharmacokinetic studies have suggested that CA-
1-P is transformed into a more reactive metabolite than CA-
4-P, which is responsible for most of the antitumoral activity;
this has formed the basis for further clinical developments
of the drug as an antivascular and antitumor agent [77]. The
drug has completed the phase I evaluation as a potential anti-
cancer drug at three different centres in the United Kingdom,
and it was studied in other phase I clinical trials [78, 79].
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Figure 4: Combretastatin A-4-P: mechanisms of action at tumor level.
Recently, a new series of combretastatin derivatives have
been synthesized and evaluated in seven cancer cell lines,
exhibiting good anticancer activity [80, 81].
2.2.3. Ombrabulin. Ombrabulin (also known as AC-7700)
is a serinamide hydrochloride, synthetic derivative of CA-
4-P, which inhibits growth in a large number of drug-
resistant animal tumors and carcinogen-induced tumors [39,
82]. Differently from CA-4-P, it does not act directly on
the tumor vessels but instead causes constriction of the
arterioles, resulting in complete downstream arrest of the
blood flow and tumor growth [83].These effects are obtained
at doses half of MTD and 100 times less than that of CA-
4-P [84]. Finally, the combination of AC-770 with cisplatin
increases the effect of both drugs in murine tumors, with
curative effects, and in human tumor xenografts [85]. In 2002,
AC-7700 was introduced into phase I clinical trials in the
United States and in Europe (AVE8062, Aventis Pharma).
Recently, ombrabulin in combination with cisplatin was used
in a phase III clinical trial for patients with advanced soft-
tissue sarcomas after failure of anthracycline and ifosfamide
chemotherapy, significantly improving progression-free sur-
vival. However, this improvement was not clinically relevant,
despite being statistically significant [86].
2.3. Dolastatins. Dolastatins are pseudopeptides isolated
from the sea hare Dolabella auricularia [50]. Dolastatins 10
and 15 showed antiproliferative activity. These agents induce
apoptosis through interactionwith tubulin [87]. Dolastatin 10
is a natural peptide able to interfere in microtubule assembly
bymeans of the noncompetitive binding to theVinca alkaloid
site [88]. A phase II trial investigated dolastatin 10 in NSCLC
patients. A low response rate was observed, even though
a good tolerability was achieved. Myelosuppression was
confirmed as the only noteworthy toxicity [89].
Other phase II clinical trials of dolastatin 10 were carried
out in patients with metastatic melanoma, advanced col-
orectal and breast cancers, recurrent platinum-sensitive ovar-
ian carcinoma, and hormone-refractory metastatic prostate
adenocarcinoma [90–94]. These studies confirmed the same
results previously obtained in terms of tumor response and
toxicity. No activitywas found in advanced pancreaticobiliary
cancers and metastatic soft-tissue sarcomas [95, 96]. For
this reason, it was suggested to not pursue the clinical
development of this drug in further studies, not only because
of its side effects [97] but also because of the low mean
survival rate of the treated patients [95].
2.3.1. Soblidotin. Soblidotin (TZT-1027) is a synthetic ana-
log of dolastatin 10 which inhibits the growth of several
tumoral cell lines and induces caspase-3-dependent apopto-
sis. It shows in vivo antivascular effects in tumoral models
overexpressing VEGF and in murine colon tumors, with
an increase in vascular permeability, vessel closure, and
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widespread hemorrhage. Soblidotin also shows antitumoral
activity in vincristine-, docetaxel-, and paclitaxel-resistant
tumors, which makes it a potential chemotherapy drug for
use in tumors which do not respond to other microtubule
inhibitors [98].
The first two European phase I clinical trials identified a
recommended dose of soblidotin between 2.4 and 2.7mg/m2
for a 3-weekly administration with neutropenia, fatigue, and
a reversible peripheral neuropathy as the DLT. Moreover
neurological side effects seemed to correlate with previous
exposure to other neurotoxic agents such as platinum com-
pounds. No correlation was found with body surface area
suggesting possible use of flat dose regimen for next trials
[99, 100]. In a Japanese phase I clinical trialMTDof 1.5mg/m2
administered on days 1 and 8 in 3-week courses was found
[101]. A combination of this drug with carboplatin was also
tested. The recommended dose was 1.5mg/m2 for soblidotin
and AUC 5 for carboplatin and no pharmacokinetics inter-
action was observed [102]. In NSCLC patients a phase I trial
indicated a recommended dose of 4.8mg/m2, administered
every 3-4 weeks as recommended dose [103].
Phase II clinical investigations suggested activity in
advanced or metastatic soft-tissue sarcomas with prior treat-
ment with anthracycline-based chemotherapy. This study
confirmed tolerability profile, but objective response was
demonstrated in none of the patients [104]. Another phase II
trial showed no anticancer activity for soblidotin in NSCLC
patients previously treated with platinum-based chemother-
apy [105].
2.3.2. Dolastatin 15. Dolastatin 15 is very similar to dolastatin
10. It was demonstrated by chromatography that the binding
domain is the same as Vinca alkaloids and antimicrotubule
peptides. The site of the binding is not a well-defined locus
but a series of overlapping domains [106]. This drug showed
an effect on growth and differentiation in leukaemia cell lines
[107], induction of apoptosis through Bcl-2 phosphorylation
in small cell lung cancer cell lines [108], and G2/M cell
cycle arrest in human myeloma cell lines [109]. Romidepsin
(Istodax), a dolastatin 15 analog, which also possesses activity
as a histone deacetylase inhibitor, was found to be active in
cutaneous T-cell lymphoma with a 34% objective response
rate and for this it was approved in 2009 [110, 111]. Other
two analogues of dolastatin 15 are used in clinical trials:
cemadotin and tasidotin.
2.3.3. Cemadotin. Cemadotin (LU103793) exerts its effect by
inhibition of microtubule polymerization [112]. This drug is
not able to inhibit the binding of vinblastine to tubulin and it
can suppressmicrotubule growthwithout a significantmicro-
tubule depolymerization [113]. This agent was first evaluated
in three phase I clinical trials for advanced refractory solid
tumors with different schedules. Daily 5-day every 3 weeks
schedule identified a recommended dose of 2.5mg/m2 per
day. It was associated with neutropenia, peripheral edema,
and liver function test abnormalities as DLTs. This dose
showed lack of prohibitive cardiovascular effects. Acceptable
general toxicity profile has allowed prompting phase II
trials [114]. Meanwhile, cemadotin was studied for 24-hour
intravenous (i.v.) continuous infusion every three weeks.
15mg/m2 was the recommended dose for this schedule.
Hypertension was highlighted as the DLT, even if its nature
remained unclear [115]. Even 5-day continuous intravenous
(CIV) infusionwas investigated.MTDwas 12.5mg/m2.There
were moderate nonhematologic toxicities and no evidence of
the cardiovascular toxicity [116]. Pharmacokinetic analysis in
these phase I trials suggested that cardiovascular toxicity may
be associated with the magnitude of the peak blood levels of
cemadotin or its metabolites, whereas myelotoxicity depends
on the duration of time that blood levels exceed a threshold
concentration.
The first phase II clinical trial which used this drug
at 2.5mg/m2 daily 5-day schedule repeated every three
weeks obtained clinical activity with durable response in
chemotherapy-na¨ıve patients with metastatic melanoma.
Toxicity profile previously determined for this schedule was
confirmed [117]. In contrast, no activitywas observedwith the
same schedule in metastatic breast cancer patients previously
treated with two lines of chemotherapy and in untreated non-
small cell cancer patients [118, 119].
2.3.4. Tasidotin. Tasidotin (ILX651) is a third-generation
dolastatin 15 analogue that is metabolically stable through its
resistance to hydrolysis [120]. It demonstrated in vitro cell
cycle arrest in the G2 and M phases and inhibition of tubulin
polymerization similar to cemadotin and the Vinca alkaloids.
It can inhibit the extent of microtubule assembly even at low
concentrations [121]. In vitro study with MCF7/GFP breast
cancer cells and in vivo pharmacokinetic analysis through
LOX tumors xenografts proposed that tasidotin is converted
in tasidotin C-carboxylate, a functionally active intracellular
metabolite, 10 to 30 times more potent [122]. Capability
of inducing apoptosis was observed in Ewing’s sarcoma,
rhabdomyosarcoma, synovial sarcoma, and osteosarcoma
cell lines. Preclinical xenograft models of pediatric sarcomas
showed antitumor activity [123].
Like cemadotin the schedule indicated for clinical use
is daily administration for 5 days every 3 weeks. The
recommended dose for investigation in phase II trial was
27.3mg/m2/day. The toxicity profile was favourable and
antitumor activity was found in melanoma patients [124].
The other two schedules were evaluated in phase I trial:
34.4mg/m2 d1,3,5 q3wk and 46.8mg/m2 d1,8,15 q4wk [125,
126]. Tolerability was similar with these schedules.
2.4. Rhizoxin. Rhizoxin (NSC 332598) is a macrolide antitu-
mor antibiotic extracted from a pathogenic fungus, Rhizopus
chinensis. It is known for its antifungal activity, but it is
also studied for cytotoxic activity in a variety of human
tumor cell lines, including melanoma, leukaemia, sarcoma,
and some human tumor xenografts of melanoma, lung, and
breast cancer [127].The drug can bind to tubulin and inhibits
microtubule assembly, blocking the cell cycle at the G2-M
phase [128]. It is a more potent cytotoxic compound than
vincristine in vitro, and, in addition, it showed activity in
vincristine-resistant cells [129].
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A recommended dose of 2.0mg/m2 administered by i.v.
bolus injection at 3-week intervals was identified through
phase I trial because of its good tolerability with mucositis
and neutropenia as the main toxicities [130]. Minimal or
absent antitumor activity was found in phase II studies for
patients with various advanced solid tumors [131–134]. A
pharmacological study demonstrated the rapid and variable
elimination of rhizoxin. These data could explain the low
levels of systemic toxicity and the little response rates [135].
For this reason, alternative dosage and schedule were studied
in phase I trial. A 72-hour continuous i.v. infusion indicated
the dose of 1.2mg/m2/72 hours as the MTD. The toxicity
profile was similar to that obtained with brief infusion, but
yet no antitumor responses were found [136].
2.5. D-24851. D-24851 (N-(pyridin-4-yl)-[1-(4-chlorbenzyl)-
indol-3-yl]-glyoxyl-amid) is a synthetic compound which
has been selected by a cell-based screening assay by ASTA
Medica AG, Germany. This drug destabilizes microtubules
by interacting with a binding site that does not overlap
with those of known microtubule-destabilizing agents like
vincristine or colchicine [137, 138].
D-24851 (also known as indibulin) induces Bcl-2 and
Bax-mediated apoptosis in both p53wt and p53−/− cell lines
[137, 139]. It produces in vivo curative effects in rat sarcomas
at nontoxic doses, is suitable for oral use, does not give
rise to neurotoxic effects at curative doses, unlike vincristine
and paclitaxel, and is effective in MDR tumor cells, so that
it is an excellent candidate as a chemotherapy agent [137].
In 2004, an LC/MS/MS (liquid chromatography/tandem
mass spectrometry) system was proposed for quantitative
analysis of D-24851 in human plasma and urine in phase I
clinical trials. Indibulin was used in phase I/II clinical trials
of patients with advanced solid tumors (metastatic breast
cancer) [27, 140, 141]. In a phase I clinical trial indibulin was
studied for oral administration once daily for 14 days every 3
weeks in patients with various solid tumors. Pharmacokinetic
analysis showed a better tolerability under feeding condition.
The recommended dose identified for further studies was
60mg daily for 14 days. Dose-limiting toxicities were nausea
and vomiting, which seemed to be related to solvent lactic
acid [141].
Furthermore, the effects of two N-heterocyclic indolyl
glyoxylamides derivatives of D-24851, BPR0C259, and
BPR0C123 were investigated in NSCLC cells. The obtained
results showed that these compounds can suppress the cell
proliferation, by inducing p53-independent apoptosis and
G2/M phase arrest, and potentially increase radiosensitivity
of human lung cancer cells in a p53-independent manner
[142].
2.6. Pseudolaric Acid B. Pseudolaric acid B (PAB) is a
diterpene isolated from Pseudolarix kaempferi Gordon which
is able to selectively inhibit the growth of actively proliferating
cancer cells. It induces apoptosis through the intrinsic path-
way, involving JNK/SAPK and p53.Nevertheless, its cytotoxic
effectswere found also in p53−/− cell lines, which is interesting
for its therapeutic use [143, 144].
It interacts with a different binding site on tubulin com-
pared with those of colchicine and vinblastine [143] and, both
in vitro and in vivo, inhibits endothelial cells proliferation
and VEGF-dependent formation of blood vessels. In fact,
PAB antagonizes VEGF-mediated antiapoptotic activity by
inhibiting the phosphorylation/activation of KDR, the VEGF
receptor implicated in mediating this effect [145]. Further-
more, at nontoxic doses, PAB inhibits VEGF secretion from
tumor cells by reducing its HIF-1-dependent transcription.
PAB, in fact, acts by accelerating the proteasome-mediated
degradation of HIF-1𝛼, by means of a mechanism so far
unknown [146]. PAB also induces endothelial cell retraction,
intercellular gap formation, and actin stress fiber formation,
effects which can be attributed to disruption of tubulin
cytoskeleton and which contribute to its antiangiogenic
action [147]. Moreover, PAB circumvents P-glycoprotein
overexpression-induced drug resistance and the doses used
are well tolerated and nontoxic and have not proved lethal
on tested animals [143]. PAB showed significant inhibitory
effect and an additive inhibitory effect in combination with
adriamycin on the growth of gastric cancer in vivo [148, 149].
2.7. Embellistatin. Embellistatin is a ketone isolated from
Embellisia chlamydospora which inhibits microtubule poly-
merization and shows a strong antiangiogenic activity. It
inhibits in vitro bovine endothelial cells (BAEC) prolifera-
tion through p53 and p21 activation, thus inhibiting bFGF-
induced formation of vessels.This antiangiogenic activity has
been confirmed in vivo on murine models. Similar effects
have been found in human tumor cell lines, suggesting that
it could be suitable for use in the development of new
anticancer drugs [150].
2.8. CI-980. CI-980 (mivobulin) acts at the colchicine bind-
ing site and it appears to have significantly less vesicant
activity than vinblastine [151]. It is a mitotic inhibitor with in
vivo and in vitro activity against murine multidrug-resistant
sublines. Its interactions with microtubules in vitro are
similar to other drugs, but cellular microtubule and mitotic
inhibition is more potent [152]. The uptake of CI-980 is not
temperature or energy dependent, and its passive diffusion
is followed by a significant but largely reversible binding to
intracellular or membrane components [153].
Mivobulin was tested in a phase I trial using 24-hour
infusion repeated every 3 weeks. MTD was 14.4mg/m2. The
main toxicities were neutropenia, dose-dependent but not
dose-limiting, and early and reversible neurotoxicity char-
acterized by dizziness, headache, loss of coordination, loss
of consciousness, nervousness, and other symptoms. Tumor
responses and tumor marker reductions were observed in a
colon cancer patient and two ovarian cancer patients, respec-
tively [154]. The same toxicity profile was confirmed in other
studies [155, 156]. A continuous 72-hour infusion of MTD
4.5mg/m2/day every 21 days was associated with reduced
neurotoxicity but dose-limiting neutropenia [157]. For this
reason, it was used in phase II clinical trials. A similar toler-
ability profile was found. CI-980 seems inactive in metastatic
colorectal carcinoma, advanced soft-tissue sarcomas, treated
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and untreated melanoma, hormone-refractory prostate can-
cer, and malignant gliomas [158, 159]. Minimal activity was
observed in platinum-refractory advanced epithelial ovarian
carcinoma [160].
2.9. T138067. T138067 is a synthetic compound which irre-
versibly disrupts microtubule assembly by a selective and
covalent binding to beta1, beta2, and beta4 isotypes of beta-
tubulin at a conserved cysteine residue (Cys-239). Its action
results in cell cycle arrest at G2/M and induction of apoptosis.
It exhibits cytotoxic activity in tumor cell lines resistant to
various antimicrotubule agents (vinblastine, paclitaxel, etc.)
and in multidrug-resistant human tumor xenografts [161].
The covalent interaction of T138067 with 𝛽-tubulin may be
proposed as a new way to overcome MDR. In vivo studies
showed that this drug can cross the blood-brain barrier in
mice, suggesting a possible use for brain tumors [162].
Phase I trials of T138067 were conducted by using a
3-hour infusion of drug given weekly or every 21 days
with a recommended dose of 330mg/m2 per week. DLTs
were neutropenia and neurological effects, consisting of
encephalopathy, headache, hearing loss, and ataxia [163, 164].
This weekly dosage was used in two phase II clinical trials
for patients with malignant glioma and metastatic colorectal
cancer previously treated with irinotecan and 5-fluorouracil,
respectively. The good toxicity profile was confirmed in both
studies. No clinical activity in terms of antitumor responses
was observed in both cases [165, 166].
2.9.1. T900607. T900607 is similar to T138067 for the kind of
binding to tubulin in Cys-239 residue, but it is distinguished
for a reduced ability to cross the blood-brain barrier.
A phase I trial indicated a recommended dose of
130mg/m2 delivered in i.v. infusion over 60 minutes on
a 21-day cycle. No objective responses were observed but
stable disease was reported in 7/20. Cardiac toxicity is the
main drug-related side effect with this schedule. A different
schedule consisting of weekly administration of T900607
identified MTD of 100mg/m2. This schedule was used in a
phase II clinical trial for untreated patients with unresectable
hepatocellular carcinoma. It showed good tolerability and
moderate activity in some of these patients [167].
2.10. ABT-751. ABT-751, also known as E7010, is a sulfon-
amide able to impair microtubule formation and inhibit
cell growth. Its binding characteristics seem to be different
from that of colchicine and Vinca alkaloids. This agent
has antiproliferative effects in many tumor cell lines which
are drug-resistant due to the P-glycoprotein overexpression
[168]. It showed a broad spectrum of activity against a
variety of tumors inmice and human tumor xenografts, when
administered orally [169]. Beta3 isotype is the preferential
binding target. ABT-751-resistant cells were characterized by
decreased expression of this tubulin isotype [170]. A warning
derived from an in vivo study, which shed light on a possible
testicular toxicity related to this drug administration in mice.
It consisted of loss of seminiferous epithelial cells due to apop-
tosis of meiotic spermatocytes [171]. This drug selectively
reduces tumor blood flow through tumor necrosis, regardless
of a direct cytotoxic effect on tumor cells. Negligible is the
effect on normal vascular function [172].
In a phase I clinical trial ABT-751 was administered
as oral single or 5-day doses. The recommended dose for
phase II trials is identified at 320mg/m2 for single dose and
200mg/m2/day for 5-day repeated dose. Peripheral neuropa-
thy and intestinal paralysis were the DLTs. Gastrointestinal
toxicity was dose-dependent but hematological toxicity was
not dose-dependent [173]. Pharmacokinetic analysis of this
study suggested that activity of ABT-751 may be time-
dependent. For this reason a new schedule using a divided
dose in order to maintain the blood level of ABT-751 has
been formulated. The recommended dose in hematologic
malignancies is 175mg/m2/day orally for 21 days every 4
weeks [174]. In a phase I trial for a pediatric population of
patients with solid tumors ABT-751 was administered orally
once daily for 21 days, repeated every 28 days. The MTD
obtained for this schedule was 100mg/m2/day. DLTs included
fatigue, sensory neuropathy, transient hypertension, neu-
tropenia, thrombocytopenia, nausea, vomiting, dehydration,
abdominal pain, and constipation [175]. In a phase II clinical
trial, 21-day every 28 days schedule at the dose of 200mg daily
was studied in taxane-refractory NSCLC patients. Toxicity
was acceptable. Median time to tumor progression and
overall survival was 2.1 and 8.4 months, respectively. The
objective response rate was 2.9% [176]. The combination
of this agent with other cytotoxic drugs was proposed for
future clinical studies. A phase IB study investigated clinical
antitumor activity of ABT-751 in combination with docetaxel
in patients with castration-resistant prostate cancer. Based
on the cumulative safety analysis, the recommended phase
II dose of ABT-751 is 200mg daily with docetaxel 60mg/m2
for this patient population [177]. Further phases I and II
clinical trials were carried out to evaluate activity of ABT-751
in combination with other drugs in advanced or metastatic
NSCLC patients [178, 179]. ABT-751 showed adverse effects,
although it has the advantage of being orally bioavailable.
3. Microtubule-Stabilizing Agents
Unlike the microtubule-destabilizing agents, there are other
compounds that enhance microtubule polymerization. One
of the most important classes of microtubule-stabilizing
chemotherapy agents is that of taxanes, which target the
cytoskeleton and spindle apparatus of tumor cells by binding
to the microtubules, thereby disrupting key cellular mech-
anisms, including mitosis. The first microtubule-stabilizing
agent used in anticancer chemotherapy [180] was paclitaxel.
Thanks to their peculiar mechanism of action, taxanes are
among the most effective chemotherapeutic agents used
in the treatment of multiple solid tumors, such as breast,
ovarian, lung, and prostate cancers. However, the occurrence
of resistance limits treatment options and creates a major
challenge for clinicians. Several potential mechanisms of
resistance to these drugs have been identified, occurring at
different pharmacodynamics levels. Besides the well-known
overexpression of Pgp, an ABC transmembrane transporter
10 Analytical Cellular Pathology
Table 2: Microtube-stabilizing agents.
Chemical lead Properties and effects Clinical trial/status References
Epothilones
Elevated water solubility, activity
versus MDR cell lines, and chemical
malleability.
Phase II/III clinical trials in
taxane-sensitive solid tumors (breast,
lung, and prostate).
[195, 196]
Ixabepilone
Epothilone B analog, superior
metabolic stability, and activity versus
MDR cell lines.
Approved in 2007 for metastatic breast
cancer; several ongoing trials in solid
tumors.
[194, 197]
Laulimalide
Activity versus MDR cell lines and
angiogenic activity, synergistic with
docetaxel.
Preclinical phase. [199, 201]
Dictyostatin Activity against MDR cell lines,synergistic with taxol. Preclinical phase. [205, 206]
which pumps the drugs out of the tumor cells [8], the
alterated expression of specific beta-tubulin isotypes, seems
to play an important role. Most notably, the increased expres-
sion of 𝛽III-tubulin isotype has been associated with resis-
tance to taxanes in several cancers, including ovarian, breast,
and lung cancer [9, 181, 182]. It was originally correlated to the
qualitative or quantitative modifications of the microtubule
complex, which represents the target of such agents, defini-
tively reducing the drug binding affinity [27]. However, the
aberrant expression of 𝛽III-tubulin can also interfere with
microtubule dynamics, increasing the dynamic instability
and counteracting the stabilizing effect of taxanes, with con-
sequences for drug sensitivity/resistance [183]. Recent studies
have suggested 𝛽III-tubulin as a prosurvival factor adaptively
expressed by cancer cells exposed to microenvironmental
stressors, such as hypoxia or deficient nutrient supply [184,
185]. The activation of the 𝛽III-tubulin-dependent pathway
in partnership with GTPases, such as guanylate-binding
protein 1 (GBP1), is associated with the incorporation of
PIM1 into the cytoskeleton of tumor cells, conferring a
survival advantage in a hostile microenvironment and ulti-
mately leading to the development of drug resistance [186].
Finally, a multitude of alterations involving the apoptotic
signaling pathways downstream the microtubule complex,
as well as aberrant expression of microRNA, have been also
found in resistant tumors. A better understanding of the
mechanism underlying the occurrence of acquired resistance
has led to the development of a new class of microtubule-
stabilizing agents, including epothilones, discodermolide,
sarcodictyins, eleutherobin, and laulimalide, which are more
readily modifiable, with different structures but a similar
mechanism of action [187] (Table 2). Epothilones, disco-
dermolide, eleutherobins, and sarcodictyins compete with
paclitaxel for binding to microtubules and bind at or near the
taxane site, whereas laulimalide seems to bind to unique sites
on microtubules (Figure 5). Recently, a novel generation of
paclitaxel derivatives have been designed, targeting a specific
intermediate binding site in the microtubule with differential
affinity, depending on the 𝛽-tubulin isotype expressed in the
tumor. Since 𝛽III-tubulin is overexpressed in the majority
of aggressive, resistant tumors, the design of a 𝛽III-tubulin
targeted agent was expected to enhance the drug activity,
reducing common toxicities. However, none of the new
molecules tested in breast cancer cell lines was superior to the
currently used taxanes [188].
3.1. Epothilones. Among several classes of microtubule-
targeting chemotherapy agents that may maintain activity
despite clinical resistance to taxanes, there are the epothilones
which have been isolated from the soil bacterium Solangium
cellulosum and have been studied most extensively in the
clinical setting [189]. They induce the formation of an
aberrant mitotic spindle, mitotic arrest, and apoptosis [190].
Their greater solubility in water and their activity in MDR
cells havemade them an alternative to paclitaxel in anticancer
treatment [191, 192]. Moreover, their simple structure makes
it easy to produce synthetic analogs during the clinical
experimentation phase [190]. There are 4 classes of natural
epothilones (A, B, C, and D). By means of the selection
of resistant or taxane-dependent cells, it has been observed
that tubulin 𝛽1 plays an important role in epothilone B
functionality [193].
Ixabepilone (Ixempra) is a semisynthetic analog of
epothilone B, selected because of its greater metabolic stabil-
ity and its simple preparation. It ismore powerful in vitro than
paclitaxel and also presents cytotoxicity against MDR cells.
It causes regression of MDR tumors and is more effective
than paclitaxel in a wide spectrum of pediatric tumors
[194]. Ixabepilone is currently the only approved epothilone
derivative and the most clinically advanced (phases II and III
clinical trials), showing efficacy in several patient subgroups
and in various stages of breast cancer. This analog is used for
the treatment of locally advanced or metastatic breast cancer
as monotherapy after failure of a taxane, an anthracycline,
and capecitabine, or in combination with capecitabine after
failure of a taxane and an anthracycline [195].
A great number of phase II clinical studies of epothilones
in cancer treatment have been reported, and significant
activity in taxane-sensitive tumor types (such as breast, lung,
and prostate cancers) has been observed [12, 17]. Response
rates in taxane-refractory metastatic breast cancer are rela-
tively modest, but ixabepilone and patupilone have shown
promising efficacy in hormone-refractorymetastatic prostate
cancer and in taxane-refractory ovarian cancer [196, 197].
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Figure 5: Similarities and differences between mechanisms of action and activity of microtubule-stabilizing agents.
3.2. Laulimalide. Laulimalide is a macrolide isolated from
marine sponge (Cacospongia mycofijiensis) which inhibits
cell proliferation, promoting assembly of the microtubules
and stabilizing them in a taxol-like way, but at a different
binding site located on two adjacent 𝛽-tubulin units between
tubulin protofilaments of amicrotubule [198–200].This agent
is also active in MDR cells which overexpress glycoprotein-P.
When administered below cytotoxic doses, the drug prevents
blood vessel formation and the VEGF-induced endothelial
cell migration [201]. Docetaxel and laulimalide possess a
synergic effect in these two processes, whereas they have
antagonistic effects towards cell proliferation.
Used at low doses, laulimalide inhibits events down-
stream of VEGFR-2 activation, such as FAK and paxillin
phosphorylation, VEGFR-2/FAK/Hsp90 interaction, and
integrin activation. Compared with docetaxel, laulimalide
has less effect on the VEGF-induced VEGFR-2/integrin 𝛼5𝛽1
interaction and is more effective with regard to phosphory-
lated paxillin levels. Furthermore, it inhibits RhoA/integrin
𝛼5𝛽1 association, suggesting that synergic effects of the two
drugs might be explained by two different modalities of
action.
The low quantities of the drug found in nature, together
with its instability caused by its transformation into iso-
laulimalide, have led to the synthesis of the drug itself and
of several analogs. The removal of a electrophilic and/or
nucleophilic group, which prevents the substitution process,
leads to major functional stability of the drug [202]. In
preclinical phase, laulimalide so far showed poor efficacy and
systematic toxicity [12]. The macrolide peloruside A shared
many of the same properties of laulimalide, including its
binding site and synergistic effects with the taxanes [203].
3.3. Dictyostatin. Dictyostatin is a macrolactone produced
from sponges which induces in vitro tubulin assembly in
the same way of paclitaxel but more rapidly. Like disco-
dermolide, this drug possesses an antiproliferative action
against paclitaxel-resistant human tumor cells as a result of𝛽-
tubulin mutations [204]. Dictyostatin inhibits the binding of
discodermolide with microtubules and both drugs are able to
inhibit the binding of epothilone B and paclitaxel withmicro-
tubules [204]. Several discodermolide/dictyostatin hybrids
have been designed and have been found tomaintain antipro-
liferative activities against several taxane-resistant cell lines
[205, 206].
3.4. Eleutherobin. Eleutherobin is a glycosylate diterpene
isolated fromEleutherobia sp. [207], which inhibits cell prolif-
eration stabilizing microtubules. It binds at a site overlapping
that of paclitaxel [208]. There is another group of cytotoxic
agents, called sarcodictyins, which are structurally and func-
tionally correlated to eleutherobins but not so toxic [209]. A
form of cytotoxic diterpene, known as (Z)-sarcodictyine A,
has been isolated from Bellonia albiflora; this exhibits a high
level of toxicity towards humanHeLa cells of the cervix [210].
Eleutherobin and the sarcodictyins have not been pursued
clinically likely due to their susceptibility to Pgp-mediated
transport [211].
4. Clinical Implications
In the last few years, a great amount of efforts has been put
into the identification of new microtubule-targeting agents
for use in anticancer therapy [212]. These last generation
agents are also active in MDR tumors, which are resistant
to the traditional antitubulin drugs used in chemotherapy,
such as Vinca alkaloids and taxanes. Furthermore, these
compounds have shown significant antivascular and antian-
giogenic activity, leading to the possibility of using them
both as alternatives to or in combination with preexistent
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drugs, as already indicated in several published studies [213].
A lot of clinical trials were conducted to study microtubule-
targeting agents. In particular, epothilones are in advanced
phases of clinical development [214, 215]. In cancer therapy,
microtubule-targeting agents can target angiogenesis, cell
migration, and intracellular trafficking to prevent tumor
growth and induce cancer cell apoptosis. These new agents,
which impair or enhance tubulin polymerization, can be clas-
sified in two groups: natural and synthetic drugs.The natural
compounds are derived from different species of uni- and
multicellular organisms. To improve their pharmacodynamic
and pharmacokinetic features some of these compounds
are transformed in semisynthetic molecules. Other agents
are produced by a totally synthetic procedure. The great
diversity of natural and synthetic compounds capable of
interactingwithmicrotubules represents an important source
for developing of novel potential anticancer agents. However,
the effectiveness of these agents in cancer therapy has been
impaired by various side effects and drug resistance. Phase I
trials have allowed identifying more tolerable schedules with
the most frequent toxicities represented by neutropenia and
neurological, cardiovascular, and gastrointestinal effects. The
main way of delivery is the i.v. infusion. Oral assumption
was studied for the synthetic compounds D-24851 and ABT-
751. The most evident efficacy was observed for rhizoxin,
above all in NSCLC. For the other agents only minor or no
responses were obtained.The identification of new schedules
or the transformation in more potent analogues should allow
overcoming these hurdles in their clinical advancement.
5. Conclusions
Data obtained up till now have allowed introducing some
of these microtubule-targeting drugs into the clinical exper-
imentation phase, whereas others, still in their preclinical
phase, represent excellent candidates for a future use in
cancer treatment, thus opening new roads towards the
development of new, individual, and efficient therapeutic
approaches.
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